Things happening back home! We were excited to host the Chief Scientist of Queensland, Prof Paul Bertsch, at Scaled for a tour and some real talk! Thanks #tradeinvestqueensland#tiq for facilitating!
Dropped in @CellStemCell - Thousands of human cardiac organoids used to discover heart regeneration drugs that don't cause arrythmias... by Scaled friends Richard Mills, @jehudson85, @PorrelloER, et al. https://t.co/O9nH74OLeP
Progress on predicting #protein structures using #AI out of @DeepMindAI. "...CASP organizers have called 'unprecedented progress in the ability of computational methods to predict protein structure'". https://t.co/YqQrjspPDc
CEO Drew Titmarsh delivering our approach and @PlateletBioGen announcement @SynBioBeta today #synbiobeta2018. Come chat more @indbio tonight if you're about!
"The agreement follows a successful pilot program that has boosted the performance economics of a critical stage of #platelet production by almost an order of magnitude." Super excited about our next chapter with @PlateletBioGen (https://t.co/d4HQrt41jn) #synbiobeta2018
We're proud to announce our latest collaboration. Working with Platelet BioGenesis (@PlateletBioGen), we will unlock a robust, economical and streamlined process for making human #Platelets! Details: https://t.co/WJzYgPThAh
Brace for impact. We're proud to kick off #SynBioBeta2018 with an exciting announcement. Be sure to tune in during the "Biopharma & Healthcare" session tomorrow @SynBioBeta (Room 1, 1.40pm) to hear our CEO, Drew Titmarsh (@dmtxbio), spill the details. More info coming soon!
Positions open! Come work with a multidisciplinary team on the cutting edge of #microfluidics, #automation, and #machinelearning to develop next generation regenerative cell therapies. Full time salary, equity and generous time off. Apply today! https://t.co/7YlHjCMRQA
Want to work with a multidisciplinary team on the cutting edge of regenerative cell therapies, using microfluidics, automation, and machine learning? Check out our new openings: https://t.co/7YlHjCMRQA
A study of 128 drugs FDA approved between 2010-2014. "Median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval" via Laura McNamee (@LMac0630) et al. https://t.co/yWC0LkwP1L @PLOS#motivation
Nice data-driven piece. "Cancer Drug Response Profile scan: A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature" via Chang et al. @Syntekabio@SciReports